Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2019-12-13 Regulatory Filings
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the suspension of share registration (shareholder register closure) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal regulatory announcement of a corporate action. Given it does not fit into specific categories like dividend announcements or share buybacks, it falls under the general regulatory filing category.
2019-12-13 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Audit Report / Information Classification · 95% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Celltrion Pharm. This is a mandatory regulatory filing in South Korea required by the Fair Trade Commission for large business groups to disclose shareholding structures, inter-company transactions, and financial relationships. Since it is a specific regulatory disclosure document that does not fit into financial reporting (10-K/IR) or other specific categories like M&A or dividends, it falls under the 'Regulatory Filings' category. Q1 2024
2019-11-27 Korean
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Celltrion Pharm, Inc. covering the period from January 1, 2019, to September 30, 2019. It contains detailed financial information, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2019
2019-11-14 Korean
특수관계인으로부터받은담보
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Celltrion Pharm regarding collateral provided by a related party (Celltrion Holdings). It details the terms of the collateral, the board's approval, and the purpose of the transaction. Since it does not fit into specific categories like M&A, dividends, or share repurchases, and is a standard regulatory disclosure under the Fair Trade Act, it is classified as a general regulatory filing.
2019-10-25 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Audit Report / Information Classification · 95% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Celltrion Pharm. This is a mandatory regulatory filing in South Korea required by the Fair Trade Commission to report on group structure, shareholdings, and inter-company transactions. Since it does not fit into specific categories like Annual Reports, Earnings Releases, or M&A, it falls under the 'Regulatory Filings' (RNS) category as a general regulatory disclosure. Q1 2024
2019-08-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure of insider share transactions (purchases, sales, or stock option exercises) by company directors or major shareholders. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2019-08-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.